愛齊科技 (ALGN) 2018 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to the Align Technology First Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ms. Shirley Stacy. Please go ahead.

    各位好,歡迎參加 Align Technology 2018 年第一季財報電話會議。(接線員指示)提醒各位,本次會議將被錄音。現在我想把會議交給主持人 Shirley Stacy 女士。請開始。

  • Shirley Stacy - VP of Corporate Communications and Investor Relations

    Shirley Stacy - VP of Corporate Communications and Investor Relations

  • Good afternoon. Thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued first quarter 2018 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com.

    各位下午好。感謝各位加入。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們今天已透過 GlobeNewswire 發布 2018 年第一季財務結果,您可在我們的網站 investor.aligntech.com 上取得。

  • Note that beginning in Q1 2018, the American region now includes the U.S., Canada and Latin America. Previously, Latin America was combined with the EMEA results for reporting purposes and included in the international total. While the Latin America region has been relatively immaterial to Align's overall results, we've adjusted our prior period regional breakouts to reflect this change so our year-over-year comps are consistent.

    請注意,自 2018 年第一季起,美洲地區現包含美國、加拿大及拉丁美洲。先前為了報導目的,拉丁美洲與 EMEA 的結果合併並納入國際合計。雖然拉丁美洲地區對 Align 整體結果相對不具重大性,我們已調整先前期間的區域拆分以反映此變更,使我們的年對年比較一致。

  • Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on May 9. To access the telephone replay, domestic callers should dial (877) 660-6853, with conference number 13678038, followed by #. International callers should dial (201) 612-7415 with the same conference number.

    今天的電話會議將以音訊網路直播,並將在我們的網站上存檔約 12 個月。電話重播將於今日美東時間約下午 5:30 起提供,至 5 月 9 日美東時間下午 5:30 止。若要收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議編號 13678038,然後按 #。國際來電者請撥打 (201) 612-7415,並使用相同的會議編號。

  • As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the second quarter of 2018. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statement. We have posted historical financial statements, including the corresponding reconciliations and our first quarter conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.

    提醒各位,今天簡報人員所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望以及 2018 年第二季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性,相關內容在我們最近向美國證券交易委員會提交的定期報告中有更詳細的說明。實際結果可能有重大差異,且 Align 明確表示不承擔更新任何前瞻性陳述的義務。我們已在網站「季度結果」(Quarterly Results) 頁面張貼歷史財務報表(含相應調節表)以及第一季電話會議簡報投影片。請參閱這些檔案以取得更詳細資訊。

  • With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    接下來,我將把電話交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights in the quarter then briefly discuss the performance of our 2 operating segments, Clear Aligners and Scanners. John will provide more detail on our financial results and discuss our outlook for the second quarter. Following that, I'll come back and summarize a few key points and open up the call to questions.

    謝謝你,Shirley。各位下午好,感謝各位加入我們。今天的電話會議中,我將先提供本季的一些重點,接著簡要說明我們兩個營運部門——透明矯正器(Clear Aligners)與掃描器(Scanners)的表現。John 將更詳細說明我們的財務結果,並討論第二季展望。之後我會回來總結幾個關鍵重點,並開放提問。

  • I'm pleased to report better-than-expected first quarter results and a strong start to the year for Align, with the revenue -- with revenues, volumes and EPS above guidance. Record Q1 revenues were up 41% year-over-year, reflecting continued strong Invisalign volume across all geographies and customer channels as well as iTero scanner sales, which are up over 84% year-over-year. Q1 Invisalign volume growth of 31% year-over-year was driven by increased utilization, including strong teen case growth globally and expansion of our customer base, which included over 4,200 new Invisalign-trained doctors worldwide.

    我很高興報告第一季結果優於預期,Align 今年開局強勁,營收——營收、出貨量與每股盈餘(EPS)均高於指引。第一季營收創新高,年增 41%,反映 Invisalign 在所有地理區域與客戶通路持續強勁的出貨量,以及 iTero 掃描器銷售年增超過 84%。第一季 Invisalign 出貨量年增 31%,主要由使用率提升所帶動,包括全球青少年病例強勁成長,以及客戶基礎擴張(全球新增超過 4,200 位完成 Invisalign 訓練的醫師)。

  • Turning to specifics around our first quarter results, let's start with results of our Americas region. Within the Americas, Q1 was a good quarter, with Invisalign volume up 7.1% sequentially and 24% year-over-year, reflecting growth in both our orthodontist and GP dentist channels. In Q1, we trained 1,600 new Invisalign doctors in the Americas region, of which 455 were in Brazil alone. We're also seeing a continued ramp-up for Invisalign treatment. For the Americas region, year-over-year growth was led by ortho customers, with another record quarter for North America ortho utilization of 15.3 cases per doctor. Q1 Invisalign utilization for our North American GP dentist were also up year-over-year, although modestly, predominantly reflecting continued expansion of the GP customer base, which included 900 from new North American GPs who submitted Invisalign cases for the first time this quarter.

    接著談第一季結果的細節,先從美洲地區的表現開始。在美洲,第一季表現良好,Invisalign 出貨量季增 7.1%、年增 24%,反映矯正專科醫師與一般牙醫(GP)兩個通路皆成長。第一季我們在美洲地區訓練了 1,600 位新的 Invisalign 醫師,其中僅巴西就有 455 位。我們也看到 Invisalign 治療持續加速成長。就美洲地區而言,年對年成長主要由矯正專科客戶帶動;北美矯正專科使用率再創單季新高,平均每位醫師 15.3 例。北美 GP 牙醫的第一季 Invisalign 使用率亦較去年同期上升,但幅度較小,主要反映 GP 客戶基礎持續擴張;其中包含本季首次提交 Invisalign 病例的 900 位北美新 GP。

  • During the quarter, we focused on key sales and marketing initiatives intended to key -- to drive growth with certain key customers. And in Q1, we continued to see higher rates among doctors in these programs than among nonparticipating doctors.

    本季期間,我們聚焦於關鍵的銷售與行銷計畫,旨在——旨在推動特定關鍵客戶的成長。而在第一季,我們持續看到參與這些計畫的醫師,其成長率高於未參與的醫師。

  • We also saw a nice uptick in Q1 from our Dental Service Organizations or DSO channel. DSOs remain a very strategic part of our overall strategy, as they look to scale operations and accelerate growth for their practices through continued investment in our end-to-end digital workflow, including Invisalign treatment and iTero scanners. At the Association of Dental Support Organizations, ADSO, meeting in Austin last week, 2 of our largest partners spoke to major DSOs about their success in integrating Invisalign treatment and digital scanning into their organizations, and our special markets team continues to build on these wins across the region.

    我們也看到第一季來自牙科服務組織(Dental Service Organizations,DSO)通路的良好提升。DSO 仍是我們整體策略中非常具策略性的部分,因為他們希望透過持續投資我們端到端的數位工作流程(包括 Invisalign 治療與 iTero 掃描器)來擴大營運規模並加速其診所成長。在上週於奧斯汀舉行的牙科支援組織協會(Association of Dental Support Organizations,ADSO)會議上,我們兩家最大的合作夥伴向主要 DSO 分享了他們在將 Invisalign 治療與數位掃描整合進其組織方面的成功經驗;我們的特殊市場團隊也持續在整個區域擴大這些成果。

  • For international doctors, Q1 was another strong quarter, with Invisalign case volume up 6.2% sequentially and 43.4% year-over-year, reflecting strong Invisalign volume across the board, driven by both increased adoption as well as expansion of our customer base, which included another 2,645 new Invisalign-trained providers, with roughly half of EMEA and half in APAC. From a customer channel perspective, while we continue to see strong growth from both the ortho and GP practices, we're beginning to see more positive traction in the GP channel from segmenting our sales and marketing resources and programs specifically around each channel.

    就國際醫師而言,第一季同樣是強勁的一季,Invisalign 病例量季增 6.2%、年增 43.4%,反映各市場全面強勁的 Invisalign 量能,主要由採用率提升以及客戶基礎擴張所帶動;其中新增 2,645 位完成 Invisalign 訓練的提供者,約一半在 EMEA、另一半在 APAC。從客戶通路角度來看,雖然矯正專科與 GP 診所皆持續強勁成長,但我們開始在 GP 通路看到更正向的動能,這得益於我們針對各通路分別配置銷售與行銷資源及方案。

  • For Q1, we're continuing to help expand the market for clear aligner treatment with approximately 1,600 newly trained doctors in EMEA, of which half were new Invisalign Go GPs. Year-over-year growth in Invisalign volume in EMEA was up 36.6%, with record volume in all but one core country market. This performance reflects continued confidence in treating complex cases with Invisalign clear aligners as well as success in the GP channel, which was up over 67% year-over-year. The growth was led by Iberia and France, which were up over 40% year-over-year. And Iberia became our third largest market worldwide for the first time, following China, our second largest market after the United States. We also saw strong growth across our key expansion markets led by Central and Eastern Europe and Benelux, where we continue to increase our sales and marketing resources across the board and have begun to implement consumer marketing programs.

    在第一季,我們持續協助擴大透明矯正治療市場,在 EMEA 約有 1,600 位新受訓醫師,其中一半為新的 Invisalign Go GP。EMEA 地區 Invisalign 出貨量年增 36.6%,除一個核心國家市場外,其餘核心國家皆創下歷史新高。此表現反映市場對以 Invisalign 透明矯正器治療複雜病例的信心持續提升,以及 GP 通路的成功(年增超過 67%)。成長主要由伊比利亞與法國帶動,兩者年增皆超過 40%。此外,伊比利亞首次成為我們全球第三大市場,僅次於美國之後的第二大市場——中國。我們也在關鍵擴張市場看到強勁成長,主要由中東歐與比荷盧(Benelux)帶動;我們持續全面增加銷售與行銷資源,並已開始導入消費者行銷方案。

  • In APAC, Q1 Invisalign volumes were up 56.1% year-over-year led by China, Japan and Australia, with China solidifying as our second largest worldwide market. Our Q1 results reflect continued strong growth overall and especially from teen cases, which are up 73% year-over-year. In addition, we saw strong growth from our GP channel, which is up over 70% compared to last year. We also continue to see positive uplift from Invisalign customers with iTero scanners. For Q1, Japan had a record quarter and showed very strong growth from doctors who have previously purchased iTero Element scanners. Finally, Q1 was an all-time high for Invisalign volume in our smaller expansion markets in Thailand, Singapore and Korea, where we are still very early in their development and adoption cycles.

    在 APAC,第一季 Invisalign 出貨量年增 56.1%,主要由中國、日本與澳洲帶動,其中中國鞏固其作為我們全球第二大市場的地位。我們第一季結果反映整體持續強勁成長,尤其是青少年病例,年增 73%。此外,我們的 GP 通路也呈現強勁成長,較去年同期增加超過 70%。我們也持續看到配備 iTero 掃描器的 Invisalign 客戶帶來正向提升。第一季日本創下歷史新高,且先前已購買 iTero Element 掃描器的醫師帶來非常強勁的成長。最後,第一季在泰國、新加坡與韓國等較小的擴張市場,Invisalign 出貨量也創下歷史新高;這些市場仍處於發展與採用週期的早期階段。

  • Now turning to the teen market. In Q1, 69.1 thousand teenagers started treatment with Invisalign clear aligners, an increase of 8.8% sequentially and 40.9% year-over-year, driven by continued strong adoption across all major regions and increasingly among younger teens and tweens. Q1 was the sixth consecutive quarter that Invisalign teenage patient volumes grew faster than adults. Overall, teen case growth is outpacing adult growth on both comprehensive and noncomprehensive products.

    接著談青少年市場。第一季有 6.91 萬名青少年開始使用 Invisalign 透明矯正器治療,季增 8.8%、年增 40.9%,主要由各主要地區持續強勁採用所帶動,且在較年輕的青少年與學齡前後(tweens)族群中的採用率也日益提高。第一季是 Invisalign 青少年患者量連續第六季成長速度快於成人。整體而言,無論是全方位(comprehensive)或非全方位(noncomprehensive)產品,青少年病例成長皆超越成人成長。

  • For Q1, year-over-year Invisalign Teen patient growth for North America's orthos increased 33%, and internationally was up 60%. The average age among teenagers continued to get younger and younger, falling 6 months over the last 7 quarters to 14 years old. This trend in average age should continue downward as we commercialize Invisalign products that support treatment of young teens and children, including Mandibular Advancement and Invisalign First, which we announced earlier this month.

    第一季,北美矯正醫師通路的 Invisalign Teen 病患數年增 33%,國際市場年增 60%。青少年平均年齡持續愈來愈低,在過去 7 個季度中下降了 6 個月,降至 14 歲。隨著我們商業化可支援年輕青少年與兒童治療的 Invisalign 產品(包括下顎前移 Mandibular Advancement 與 Invisalign First;我們已於本月稍早宣布),此平均年齡下降的趨勢應會持續。

  • Invisalign Teen with Mandibular Advancement, or MAF as we call it, continues to ramp internationally. It is currently pending FDA approval in the United States, which is slotted for approval in the second half of this year. The lift analysis that we have suggests a direct halo effect from MAF users that results in a higher percentage of teenagers treated with Invisalign clear aligners.

    Invisalign Teen 搭配下顎前移(Mandibular Advancement),我們稱之為 MAF,持續在國際市場加速推進。目前在美國仍待 FDA 核准,預計於今年下半年取得核准。我們的提升(lift)分析顯示,MAF 使用者帶來直接的光環效應(halo effect),使以 Invisalign 透明牙套治療的青少年占比提高。

  • Invisalign First clear aligners is a new Invisalign treatment designed with features specifically for younger patients with early mixed dentition. Phase I treatment, which makes up roughly 20% of case starts each year, is early interceptive orthodontic treatment, traditionally done through arch expanders or partial metal braces before all permanent teeth have erupted, typically ages 6 through 10. To date, Invisalign First clear aligners have been used to treat over 600 patients and will be commercially available beginning July 1 in 2018.

    Invisalign First 透明牙套是一項新的 Invisalign 治療方案,具備專為較年幼、處於早期混合齒列(early mixed dentition)的患者所設計的功能。第一期(Phase I)治療約占每年新開案(case starts)的 20%,屬於早期攔截性矯正治療;傳統上會在所有恆牙尚未萌出前,透過牙弓擴張器或部分金屬矯正器進行,通常適用年齡為 6 至 10 歲。迄今為止,Invisalign First 透明牙套已用於治療超過 600 名患者,並將自 2018 年 7 月 1 日起開始商業供應。

  • Earlier this month, we announced an expanded Invisalign product portfolio that includes new options and greater flexibility to treat a broader range of patients. The revamped Invisalign product portfolio offers doctors more choices by extending desirable features across the entire portfolio and creating Invisalign treatment packages as well as the new Invisalign First option to treat young patients with early mixed dentition. The new Invisalign clear aligner treatment options will be effective July 1, 2018.

    本月稍早,我們宣布擴充 Invisalign 產品組合,納入新選項並提供更高彈性,以治療更廣泛的患者族群。更新後的 Invisalign 產品組合,透過將受歡迎的功能延伸至整個產品線,並建立 Invisalign 治療套裝方案,以及新增 Invisalign First 選項以治療早期混合齒列的年幼患者,為醫師提供更多選擇。新的 Invisalign 透明牙套治療選項將自 2018 年 7 月 1 日起生效。

  • Today, we announced a new more user-friendly version of our Invisalign Go product and digital platform that offers greater flexibility and expanded treatment options for simple teeth straightening cases. Invisalign Go offers intuitive Invisalign experience design for GPs worldwide, who are seeking to integrate clear aligner therapy into their thriving comprehensive dentistry practices.

    今天,我們宣布推出更易用版本的 Invisalign Go 產品與數位平台,為簡單牙齒排列矯正病例提供更高彈性與更豐富的治療選項。Invisalign Go 為全球一般牙科醫師(GPs)提供直覺式的 Invisalign 體驗設計,協助其將透明牙套治療整合至蓬勃發展的全方位牙科診療業務中。

  • We started the year off with strong consumer interest in the first quarter, over 4 million unique visitors to Invisalign websites worldwide, up 54% from the same quarter last year. More than 500,000 potential patients searched for an Invisalign provider on our doc locator webpage, up 27% from the same quarter last year. Almost 220,000 consumers opted in for follow-up, and the Invisalign social media community grew over 20% year-over-year, adding 688,000 consumers, who are following the Invisalign brand worldwide. All metrics for tracking consumer interest are up, with especially strong growth in website visitors across APAC and opt-ins in the Americas region.

    今年第一季,我們以強勁的消費者興趣開局:全球 Invisalign 網站的獨立訪客超過 400 萬人次,較去年同期成長 54%。超過 50 萬名潛在患者在我們的醫師搜尋(doc locator)網頁上查找 Invisalign 供應醫師,較去年同期成長 27%。近 22 萬名消費者選擇留下資料以便後續聯繫(opted in for follow-up),而 Invisalign 社群媒體社群年增超過 20%,新增 688,000 名關注 Invisalign 品牌的消費者(遍及全球)。所有追蹤消費者興趣的指標皆上升,其中以亞太地區(APAC)網站訪客成長,以及美洲地區的留資(opt-ins)成長尤為強勁。

  • During the quarter, we also expanded on our customer outreach through the addition of our second Invisalign pilot store near our headquarters in San Jose, California. We're seeing great initial ramp-up in both San Francisco and San Jose stores as we connect consumers to authorized Invisalign providers, and we'll continue to monitor store activity. The Invisalign stores are a doctor-based model. Consumers who visit an Invisalign store are referred to a doctor's office, where a doctor performs a personal clinical examination of the patient and a treatment plan. The doctor will follow the patient until the case is completed. In Q2, we are opening 2 additional pilot stores on East Coast, one in Bethesda, Maryland and another in the Philadelphia area. We look forward to continuing to learn more from these 4 locations and sharing our progress throughout the year.

    本季度,我們也透過在加州聖荷西(San Jose)總部附近新增第二家 Invisalign 試點門市,擴大客戶觸達。我們看到舊金山與聖荷西兩家門市在初期皆有良好的成長動能,因為我們協助消費者連結至授權的 Invisalign 供應醫師;我們將持續監測門市活動。Invisalign 門市採醫師主導(doctor-based)模式。造訪 Invisalign 門市的消費者會被轉介至醫師診所,由醫師對患者進行個人臨床檢查並制定治療計畫,並由醫師一路追蹤患者直到療程完成。第二季,我們將在美國東岸再開設 2 家試點門市,一家位於馬里蘭州貝塞斯達(Bethesda),另一家位於費城地區。我們期待持續從這 4 個據點獲得更多學習,並在全年分享我們的進展。

  • As we head into our highest investment period of the year for our consumer marketing program, which includes the very important summer season for teenage case starts, we plan to increase spend across mom and teen marketing programs to focus on raising awareness and turning more consumers into Invisalign patients through our doctors' offices.

    隨著我們進入全年消費者行銷計畫投資最高的期間(其中包含對青少年新開案非常重要的暑期旺季),我們計畫提高在媽媽與青少年行銷方案上的支出,聚焦提升認知度,並透過醫師診所將更多消費者轉化為 Invisalign 患者。

  • In Q1, iTero revenues were down 10% sequentially as expanded -- as expected, following a strong Q4, which reflected year-end seasonality in the capital equipment business. Year-over-year, Q1 scanners were up 84%, reflecting very strong growth across all regions and reflects how central a digital approach is to overall customer utilization of Invisalign treatments. Use of iTero scanners for Invisalign case submissions in place of PVS impressions continues to expand and remains a positive catalyst for Invisalign utilization. For first quarter, total Invisalign cases submitted with a digital scanner in the Americas increased to a record 67.2%, up from 65.3% in Q4 last year. International scans increased 43.1%, up from 41.4% in Q1 last year. To date, more than 7.7 million orthodontic scans and 2.7 million restorative scans have been started with iTero scanners.

    第一季,iTero 營收較前一季下滑 10%,如預期,係因第四季表現強勁,而資本設備業務在年底具有季節性因素。以年增率來看,第一季掃描器出貨量成長 84%,反映各區域皆有非常強勁的成長,也顯示數位化方法在客戶整體使用 Invisalign 治療中居於核心地位。以 iTero 掃描器提交 Invisalign 病例、取代 PVS 印模的使用持續擴大,並仍是推動 Invisalign 使用量的正向催化劑。第一季,美洲地區以數位掃描器提交的 Invisalign 病例占比提升至創新高的 67.2%,高於去年第四季的 65.3%。國際市場的掃描占比提升至 43.1%,高於去年第一季的 41.4%。截至目前,使用 iTero 掃描器已啟動超過 770 萬次矯正掃描與 270 萬次修復(restorative)掃描。

  • Today, we announced the expansion of our iTero Element portfolio, with the launch of the iTero Element 2 and the iTero Element Flex scanners. These additions build on the existing high precision, full-color imaging and fast scan times of iTero Element portfolio while streamlining orthodontic and restorative workflows. The next-generation iTero Element 2 is designed for greater performance with 2x faster startup and 25% faster scan processing times compared to iTero Element. The new iTero Element Flex is a wand-only device that transforms compatible laptop computers into a highly portable scanner that works anywhere. It's perfect for practices with multiple locations who need a scanner that is both convenient and easy to transport. The new scanners will be showcased at the AAO meeting next week.

    今天,我們宣布擴充 iTero Element 產品組合,推出 iTero Element 2 與 iTero Element Flex 掃描器。這些新增產品在既有 iTero Element 產品組合的高精度、全彩影像與快速掃描時間基礎上,進一步精簡矯正與修復的工作流程。新一代 iTero Element 2 以更高效能為設計目標,相較 iTero Element,開機速度快 2 倍,掃描處理時間快 25%。全新的 iTero Element Flex 為僅手持掃描棒(wand-only)裝置,可將相容的筆記型電腦轉變為高度可攜式、可在任何地方使用的掃描器。它非常適合擁有多個據點、需要兼具便利性與易於運輸之掃描器的診所。新掃描器將於下週的 AAO 會議上亮相。

  • Today, we also announced that we'll have received market approval for iTero Element Intraoral Scanner for the -- from the CFDA. That's the China Food and Drug Administration, and we have begun offering the iTero Element Scanner in China. Intraoral scanners have less than a 2% penetration rate in China today and are expected to grow 6x by 2020. The iTero Element Scanner launch in China not only supports growth of our base Invisalign clear aligner business but also represents a major milestone for digital dentistry in China.

    今天,我們也宣布已取得 iTero Element 口內掃描器(Intraoral Scanner)在中國的市場核准,核准機關為 CFDA(中國食品藥品監督管理局),並已開始在中國提供 iTero Element 掃描器。口內掃描器在中國目前的滲透率低於 2%,預期至 2020 年將成長 6 倍。iTero Element 掃描器在中國的上市不僅支援我們既有 Invisalign 透明牙套業務的成長,也代表中國數位牙科的一項重要里程碑。

  • Finally, in the doctor-directed, at-home channel, Align is a third-party supplier to SmileDirectClub, with a 19% equity investment in the company. We manufacture a portion of SDC aligners, which are non-Invisalign clear aligners. For Q1, shipments to SDC were down sequentially as expected, reflecting SDC's desire to produce their own clear aligners. Today, we issued a separate press release commenting on SDC's allegation that the launch and operation of our Invisalign store pilot program constitutes a breach of noncompete provisions. As disclosed previously, we dispute SDC's allegations and intend to continue Invisalign store pilot program, and we oppose and defend ourselves in these proceedings. While this dispute does not impact our existing supply agreement with SDC, which is in effect through 2019, we anticipate minimal volume from SDC in Q2 in the second half of 2018.

    最後,在醫師導向的居家(at-home)通路方面,Align 是 SmileDirectClub(SDC)的第三方供應商,並持有該公司 19% 的股權投資。我們製造部分 SDC 牙套(非 Invisalign 的透明牙套)。第一季,對 SDC 的出貨量如預期較前一季下降,反映 SDC 希望自行生產其透明牙套。今天,我們另行發布新聞稿,回應 SDC 指稱我們啟動並營運 Invisalign 門市試點計畫構成違反競業禁止條款的主張。如先前揭露,我們不同意 SDC 的指控,並打算持續推動 Invisalign 門市試點計畫;同時,我們將在相關程序中提出反對並為自身辯護。雖然此爭議不影響我們與 SDC 既有的供應協議(有效至 2019 年),但我們預期 2018 年下半年第二季來自 SDC 的出貨量將極少。

  • With that, I'll turn it over to John.

    接下來,我把時間交給 John。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Thanks Joe. Now for our Q1 financial results. Total company revenue for the first quarter was a record $436.9 million, up 3.7% from the prior quarter and up 40.8% from the corresponding quarter a year ago. Year-over-year revenue growth includes a 5-point benefit from favorable foreign exchange. Clear aligner revenue of $385.5 million was up 5.8% sequentially on higher-than-expected volume. Year-over-year clear aligner revenue growth, up 36.5%, reflected strong Invisalign shipment growth across all customer channels and geographies and increased Invisalign ASPs. Q1 Invisalign ASPs were up sequentially, approximately $5 from Q4 to $1,310, reflecting favorable foreign exchange and product mix, partially offset by sales promotions and revenue deferrals. On a year-over-year basis, Q1 Invisalign ASPs were up approximately $40, reflecting favorable foreign exchange, price increases and product mix, partially offset by sales promotions and deferrals related to additional aligners.

    謝謝 Joe。接著說明我們第一季的財務結果。公司第一季總營收創下紀錄,達 4.369 億美元,較前一季成長 3.7%,較去年同期成長 40.8%。年增營收成長包含外匯有利變動帶來的 5 個百分點貢獻。透明牙套營收為 3.855 億美元,因出貨量高於預期,較前一季成長 5.8%。透明牙套營收年增 36.5%,反映 Invisalign 在所有客戶通路與各地區的出貨成長強勁,以及 Invisalign 平均銷售單價(ASP)提高。第一季 Invisalign ASP 較前一季上升,約較第四季增加 5 美元至 1,310 美元,反映外匯有利變動與產品組合,部分被銷售促銷與營收遞延所抵銷。以年增來看,第一季 Invisalign ASP 約增加 40 美元,反映外匯有利變動、價格調升與產品組合,部分被銷售促銷以及與額外牙套相關的遞延所抵銷。

  • For the first quarter, total Invisalign shipments of 272.2 thousand cases were up 6.7% sequentially and up 30.8% year-over-year, driven by growth across all regions. For Americas orthodontists, Q1 Invisalign case volume was up 8.5% sequentially and up 27% year-over-year. For Americas GP dentists, Invisalign case volume was up 5.1% sequentially and up 19.6% year-over-year. For international doctors, Invisalign case volume was up 6.2% sequentially and up 43.4% year-over-year. Our scanner and services revenue for the first quarter was $54.4 million, down 10% sequentially due to the lower volume from the Q4 seasonality effect and up 84% year-over-year, primarily due to higher volume, partially offset by lower ASPs due to promotions and discounts.

    第一季,Invisalign 總出貨量為 272.2 千例,較前一季成長 6.7%,較去年同期成長 30.8%,成長動能來自所有地區的增長。就美洲地區矯正專科醫師而言,第一季 Invisalign 病例量較前一季成長 8.5%,較去年同期成長 27%。就美洲地區一般牙醫(GP)而言,Invisalign 病例量較前一季成長 5.1%,較去年同期成長 19.6%。就國際醫師而言,Invisalign 病例量較前一季成長 6.2%,較去年同期成長 43.4%。第一季掃描儀與服務營收為 5,440 萬美元,較前一季下降 10%,主要因第四季季節性效應導致量較低;較去年同期成長 84%,主要由較高的出貨量帶動,但部分被促銷與折扣造成的平均售價(ASP)下降所抵銷。

  • Moving on to gross margin. First quarter overall gross margin was 74.9%, down 0.6 points sequentially and down 1 point year-over-year. Clear aligner gross margin for the first quarter was 77%, down 0.6. points sequentially, primarily due to increased aligners per case and higher training cost, partially offset by higher Invisalign ASPs. Clear aligner gross margin was down 0.9 points year-over-year, primarily due to regional expansion of our manufacturing activities, partially offset by higher worldwide ASPs. Scanner gross margin for the first quarter was 59.2%, down 2.8 points sequentially due to lower scanner ASPs related to promotions and discounts. Scanner gross margins were up 3.1 points year-over-year, primarily due to lower services costs, partially offset by lower scanner ASPs.

    接著談毛利率。第一季整體毛利率為 74.9%,較前一季下降 0.6 個百分點,較去年同期下降 1 個百分點。第一季透明牙套毛利率為 77%,較前一季下降 0.6 個百分點,主要因每例使用的牙套數增加以及培訓成本較高,部分被 Invisalign 平均售價(ASP)較高所抵銷。透明牙套毛利率較去年同期下降 0.9 個百分點,主要因我們製造活動的區域擴張,部分被全球平均售價較高所抵銷。第一季掃描儀毛利率為 59.2%,較前一季下降 2.8 個百分點,原因是與促銷與折扣相關的掃描儀平均售價較低。掃描儀毛利率較去年同期上升 3.1 個百分點,主要因服務成本較低,部分被掃描儀平均售價較低所抵銷。

  • Q1 operating expenses were $229.2 million, up sequentially 10% and up 31.8% year-over-year. The increase in operating expenses reflects continued investment in our go-to-market activities, including higher advertising spending, geographic expansion as well as increased compensation related to expenses due to higher headcount and our planned annual increase in employee compensation programs.

    第一季營業費用為 2.292 億美元,較前一季增加 10%,較去年同期增加 31.8%。營業費用的增加反映我們持續投資於市場推廣(go-to-market)活動,包括更高的廣告支出、地理擴張,以及因員工人數增加與我們規劃中的年度員工薪酬方案調升而帶來的薪酬相關費用增加。

  • Our first quarter operating income was $98.2 million, down 10.4% sequentially and up 59.2% year-over-year. Our first quarter operating margin was 22.5%, down 3.5 points sequentially and up 2.6 points year-over-year. The sequential decrease in operating margin relates primarily to lower gross margin due to operational expansion activities; higher operating expenses, as just described; and lower SmileDirectClub-related revenue. On a year-over-year basis, the increase in operating margin primarily reflects higher revenues from both clear aligner and scanner and services as well as favorable foreign exchange rates.

    第一季營業利益為 9,820 萬美元,較前一季下降 10.4%,較去年同期成長 59.2%。第一季營業利益率為 22.5%,較前一季下降 3.5 個百分點,較去年同期上升 2.6 個百分點。營業利益率的季比下降主要與以下因素相關:因營運擴張活動導致毛利率較低;如前所述營業費用較高;以及與 SmileDirectClub 相關的營收較低。以年比來看,營業利益率的提升主要反映透明牙套以及掃描儀與服務兩項業務營收增加,並受惠於有利的匯率變動。

  • With regards to the first quarter tax provision, our tax rate was 2.9%, which includes $23.3 million in excess tax benefits related to stock-based compensation and is down by approximately 89.5 points compared to 92.4% in Q4 of 2017, primarily due to the U.S. Tax Cuts and Jobs Act enacted in December last year. First quarter diluted earnings per share was $1.17, up $1.04 sequentially and up $0.32 compared to the prior year. Recall that Q4 2017 diluted earnings per share of $0.13 included $86.6 million expense or $1.06 per diluted share impact due to the U.S. Tax Cuts and Jobs Act.

    就第一季所得稅提列而言,我們的稅率為 2.9%,其中包含與股票基礎薪酬相關的 2,330 萬美元超額稅務利益,較 2017 年第四季的 92.4% 約下降 89.5 個百分點,主要因去年 12 月通過的《美國減稅與就業法案》(U.S. Tax Cuts and Jobs Act)。第一季稀釋後每股盈餘為 1.17 美元,較前一季增加 1.04 美元,較去年同期增加 0.32 美元。提醒一下,2017 年第四季稀釋後每股盈餘 0.13 美元包含因《美國減稅與就業法案》而產生的 8,660 萬美元費用,或對稀釋後每股影響 1.06 美元。

  • Finally, Q1, we adopted ASC 606, revenues from contracts with customers using the full retrospective method. While the impact to the Q1 2017 and Q1 2018 P&Ls are immaterial, the condensed consolidated balance sheet as of December 31, 2017, has been recasted to comply with ASC 606 requirements.

    最後,第一季我們採用 ASC 606《與客戶合約之收入》,並使用完全追溯法。雖然對 2017 年第一季與 2018 年第一季損益表(P&L)的影響不重大,但截至 2017 年 12 月 31 日的簡明合併資產負債表已重新表達,以符合 ASC 606 的要求。

  • Moving on to the balance sheet. As of the first quarter, cash, cash equivalents and marketable securities, including both short- and long-term investments, were $673 million. This compared to $761.5 million at the end of 2017, a decrease of approximately $88.5 million, primarily due to $100 million in stock repurchased during the quarter. Of our $673 million of cash, cash equivalent and marketable securities, $236 million was held in the U.S. and $436.2 million was held by our international entities. Q1 accounts receivable balance was $361.5 million, up approximately 11.5% sequentially. Our overall days sales outstanding, DSOs, was 74 days, up 5 days sequentially and down 3 days from 77 days in Q1 last year. Even though our accounts receivable aging profile has improved, the Q1 DSO was up sequentially as a result of increased sales with extended payment terms that are available in certain regions.

    接著看資產負債表。截至第一季末,現金、約當現金與有價證券(包含短期與長期投資)為 6.73 億美元。相較於 2017 年底的 7.615 億美元,約減少 8,850 萬美元,主要因本季回購股票 1 億美元。在 6.73 億美元的現金、約當現金與有價證券中,2.36 億美元持有於美國,4.362 億美元由我們的海外實體持有。第一季應收帳款餘額為 3.615 億美元,較前一季增加約 11.5%。整體應收帳款週轉天數(DSO)為 74 天,較前一季增加 5 天,較去年第一季的 77 天下降 3 天。儘管我們的應收帳款帳齡結構已有改善,但第一季 DSO 仍較前一季上升,原因是某些地區提供延長付款條件,使得採用延長付款條件的銷售增加。

  • Capital expenditures for the first quarter were $57.6 million, primarily related to building purchases and improvements, equipment purchases for additional manufacturing capacity as well as our global expansion efforts, including the new manufacturing facility in Ziyang, China mentioned last quarter. Cash flow from operations for the first quarter was $77.3 million, up $29.7 million compared to the prior year. Free cash flow from the first quarter, defined as cash flow from operations less capital expenditures, amounted to $19.7 million.

    第一季資本支出為 5,760 萬美元,主要用於建物購置與改善、為增加製造產能而購置設備,以及我們的全球擴張計畫,包括上季提到位於中國資陽的新製造工廠。第一季營運活動現金流量為 7,730 萬美元,較去年同期增加 2,970 萬美元。第一季自由現金流量(定義為營運活動現金流量減資本支出)為 1,970 萬美元。

  • During the first quarter, we also repurchased approximately 400,000 shares of stock for $100 million under the April 2016 repurchase program. We have $100 million remaining available for repurchase under this existing stock repurchase authorization. Other significant cash flow activities during the quarter included the receipt of $30 million from SmileDirectClub for repayment of their existing line of credit, and we paid $47.8 million in employees' taxes upon vesting of restricted stock units.

    第一季期間,我們亦依據 2016 年 4 月的回購計畫,以 1 億美元回購約 40 萬股股票。在現有的股票回購授權下,尚有 1 億美元可供回購。本季其他重要的現金流活動包括:自 SmileDirectClub 收到 3,000 萬美元,用於償還其既有的信用額度;以及在限制型股票單位(RSU)歸屬時,我們代員工支付 4,780 萬美元的員工稅款。

  • With that, let's turn to our Q2 outlook and the factors that inform our view, starting with the demand outlook. We expect our international business to grow significantly on a sequential basis as the European market is coming out of their winter season and most of the APAC market were observing Lunar New Year in the first quarter. For the Americas region, we expect Q2 to grow as our ortho and GP customers are seasonally busier and as we continue to make progress in our Latin America expansion. We continue to invest in our iTero go-to-market activities. We started selling iTero Element in Brazil in Q1, and we have started selling iTero Element in China in Q2. We expect sequential increase in iTero units sold and revenues.

    接下來我們談第二季展望,以及支撐我們觀點的因素,先從需求展望開始。隨著歐洲市場走出冬季,以及亞太(APAC)多數市場在第一季適逢農曆新年,我們預期國際業務將在季比基礎上顯著成長。就美洲地區而言,我們預期第二季將成長,因為矯正專科與一般牙醫客戶在季節性上更為忙碌,且我們持續推進拉丁美洲擴張。我們持續投資於 iTero 的市場推廣(go-to-market)活動。我們已於第一季開始在巴西銷售 iTero Element,並於第二季開始在中國銷售 iTero Element。我們預期 iTero 銷售台數與營收將較前一季增加。

  • As Joe mentioned earlier, we are currently in litigation with SmileDirectClub regarding our Invisalign store pilot, and while this does not impact our supply agreement, the state of our relationship, we are assuming minimum volumes for SmileDirectClub in Q2 and the second half in '18.

    如 Joe 先前提到,我們目前就 Invisalign 門市試點與 SmileDirectClub 進行訴訟;雖然這不影響我們的供應協議,但就我們雙方關係的現況而言,我們在第二季以及 2018 年下半年對 SmileDirectClub 的出貨量假設採取最低量。

  • With this as a backdrop, we expect the second quarter to shape up as follows. Invisalign case volume is expected to be in the range of 296,000 to 301,000 cases, up approximately 28% to 30% over the same period a year ago. We expect Q2 net revenues to be in the range of $460 million to $470 million, an increase of approximately 29% to 32% year-over-year. We expect Q2 gross margin to be in the range of 74.2% to 75%, reflecting higher expenses as we regionalize our treatment planning and manufacturing operations, partially offset by higher ASPs. We expect Q2 operating expenses to be in the range of $245 million to $250 million, up on a sequential basis to reflect our continued investment in go-to-market activities. Q2 operating margin should be in the range of 21% to 21.8%. Our effective tax rate, including an excess tax benefit of about $10 million, should be approximately 13%. We expect a $1 million to $2.5 million loss related to our share of SmileDirectClub. And diluted shares outstanding should be approximately 81.6 million, exclusive of any share repurchases. Taken together, we expect our Q2 diluted earnings per share to be in the range of $1.02 to $1.06. In addition, as we continue to operational -- our operational expansion efforts, we expect CapEx for Q2 to be approximately $65 million to $70 million, and we expect depreciation and amortization to be $10 million to $11 million.

    在此背景下,我們預期第二季表現如下:Invisalign 病例量預計介於 296,000 至 301,000 例,較去年同期約成長 28% 至 30%。我們預期第二季淨營收介於 4.60 億至 4.70 億美元,較去年同期增加約 29% 至 32%。我們預期第二季毛利率介於 74.2% 至 75%,反映我們在治療規劃與製造營運區域化過程中費用較高,部分由較高的平均售價(ASP)所抵銷。我們預期第二季營業費用介於 2.45 億至 2.50 億美元,季比上升以反映我們持續投資於市場推廣(go-to-market)活動。第二季營業利益率應介於 21% 至 21.8%。我們的有效稅率(包含約 1,000 萬美元的超額稅務利益)應約為 13%。我們預期與我們分攤 SmileDirectClub 相關的損失為 100 萬至 250 萬美元。稀釋後流通在外股數約為 8,160 萬股,不含任何股票回購。綜合以上,我們預期第二季稀釋後每股盈餘介於 1.02 至 1.06 美元。此外,隨著我們持續推進營運擴張工作,我們預期第二季資本支出約為 6,500 萬至 7,000 萬美元,折舊與攤銷預期為 1,000 萬至 1,100 萬美元。

  • Now let me turn to our view of 2018. Based on the momentum in our business to date and our planned investments for the remainder of the year, we now anticipate 2018 total revenue growth rate to be above our long-term model and in the low 30s. We also expect Invisalign volume and -- revenue and volume to be -- growth in that same range. Notwithstanding continued investments in our strategic growth drivers, we expect the operating margin for the full year to be flat to slightly up from 2017 operating margin of 24%.

    現在我來談談我們對 2018 年的看法。根據截至目前我們業務的動能,以及我們在今年剩餘期間規劃的投資,我們現在預期 2018 年全年總營收成長率將高於我們的長期模型,約在 30% 出頭。我們也預期 Invisalign 的出貨量以及——營收與出貨量——的成長將落在同樣的區間。儘管我們仍將持續投資於策略性成長驅動因素,我們預期全年營業利益率將與 2017 年 24% 的營業利益率持平至略為上升。

  • With that, I'll turn it back over to Joe for final comments. Joe?

    接下來,我把時間交回給 Joe 做最後的評論。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, John, and thanks to those for joining the call today. I'm pleased with our start to 2018 as well as our continued progress in execution of our strategic growth drivers. There are a lot of changes happening in dentistry and orthodontics today, but the industry remains healthy, and I think customers are starting to see new opportunities for how they treat patients and reach new customers.

    謝謝你,John,也感謝今天加入電話會議的各位。我對我們 2018 年的開局,以及我們在執行策略性成長驅動因素方面持續取得的進展感到滿意。當今牙科與齒顎矯正領域正在發生許多變化,但產業仍然健康,我認為客戶也開始看到在治療病患以及觸及新客戶方面的全新機會。

  • We're looking forward to an exciting and productive AAO meeting in Washington, D.C., where we'll get to showcase our new products on the scanner side and also with Invisalign First. We're also going to have a pop-up version of our Invisalign pilot store as a way to answer customer questions and to get their perspective on our program. Then we'll be in Singapore at the end of May hosting our third Asia Pacific summit, where we'll be expecting about 1,000 delegates from across the region, attending a 2-day peer-to-peer education event. We've got a lot going on in Q2, and I look forward to sharing more with you at our upcoming financial conference at our Investor Day in New York on Monday, May 20 -- I'm sorry, on May 23.

    我們期待在華盛頓特區舉行一場令人振奮且富有成效的 AAO 會議,屆時我們將展示掃描器端的新產品,以及 Invisalign First。我們也將推出 Invisalign 試點門市的快閃版本,以回答客戶問題並取得他們對我們方案的看法。接著在 5 月底,我們將在新加坡主辦第三屆亞太高峰會,預計將有約 1,000 位來自全區的代表參與,出席為期 2 天的同儕對同儕教育活動。第二季我們有很多事情在進行中,我也期待在即將到來的財務會議、以及 5 月 20 日(星期一)在紐約的投資人日與各位分享更多——抱歉,是 5 月 23 日。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Not a Monday for sure.

    肯定不是星期一。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • On May 23.

    5 月 23 日。

  • With that, I'll turn it over to the operator, and we'll open up to your questions.

    那麼,我把時間交給接線員,我們將開放各位提問。

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from Robert Jones of Goldman Sachs.

    (接線員指示)我們的第一個問題來自高盛(Goldman Sachs)的 Robert Jones。

  • Robert Patrick Jones - VP

    Robert Patrick Jones - VP

  • Joe, just looking at the expected new revenue growth rate for the year now above the long-term model, I'm sure it's a combination of several factors. But I was hoping maybe you could just, maybe in rank order, attribute what really has gone better than expected so early in the year if we think about teen off to a good start and the new product launches. Obviously, iTero seems to be pacing much better than certainly we were expecting. Could you maybe just give us some insight into what out of the gate this year has gone better than planned?

    Joe,從你們現在預期全年新的營收成長率高於長期模型來看,我相信這是多項因素的組合。不過我希望你能否——也許按重要性排序——說明一下,今年這麼早就有哪些事情表現得比預期更好?如果我們想到青少年業務有個不錯的開局以及新產品上市。顯然 iTero 的進度看起來比我們原先預期好得多。你能否分享一些洞見,說明今年一開始有哪些地方進展得比計畫更好?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Well, we had an aggressive plan for the year. But to start off, I'd say -- we look at the international business. It continues to be very strong with APAC and EMEA. Really good performance in the Americas, particularly around North America, too. If we start to segment it, you mentioned it, our teen product is up pretty substantially that way. iTero sales have been terrific in that sense. We talk about how customers more and more are recognizing that whole digital workflow and how important it is. And you can see with our scanning now in North America and being close to 67%, that's just really working out well. And we know when they purchase iTero scanner, we see more Invisalign sales.

    嗯,我們今年的計畫很積極。但如果要先說,我會——先看國際業務。APAC 與 EMEA 持續非常強勁。美洲地區表現也很好,尤其是北美。如果進一步拆分,你提到了,我們的青少年產品在那方面成長相當顯著。iTero 的銷售在這個意義上也非常出色。我們一直在談,客戶愈來愈認知到整體數位工作流程以及其重要性。你也可以看到,我們在北美的掃描滲透率接近 67%,這確實運作得很好。而且我們知道,當客戶購買 iTero 掃描器時,我們會看到更多 Invisalign 的銷售。

  • Lastly, I'd say our segmentation, I mentioned it in my script, too, is the segmentation of GP and ortho very specifically and also segmenting consumers in the sense of our concierge service and how more and more we target consumers and lead them into the specific docs from a doc locator standpoint. That's gone a little better than expected, too. So overall, the company has been executing well across geographies and across our segmentation and product plans.

    最後我會說,我們的分眾——我在講稿裡也提到——也就是非常明確地區分一般牙醫(GP)與矯正專科(ortho),同時在消費者端也做分眾,例如我們的禮賓服務,以及我們如何愈來愈多地鎖定消費者,並從醫師搜尋(doc locator)的角度把他們導向特定醫師。這部分的表現也比預期好一些。總體而言,公司在各地區、以及我們的分眾與產品計畫上都執行得很好。

  • Robert Patrick Jones - VP

    Robert Patrick Jones - VP

  • Great, and I appreciate that. And then it looks like you're seeing some early traction already from Invisalign First. I was wondering if maybe you could share with us how that launch of a product like that changes the addressable market that you can actually go after. Just getting some thoughts from you would be helpful around how much more expanded the younger market becomes with a product like First.

    很好,謝謝你的說明。接著看起來你們已經從 Invisalign First 看到一些早期動能。我想請你分享一下,像這樣的產品上市,會如何改變你們實際可切入的可服務市場(addressable market)。也想聽聽你的想法:有了 First 這樣的產品之後,較年幼市場的規模會擴大多少?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. First of all, those 600 cases we did -- that product launches in July. Those were actually just cases we put in place from a clinical study standpoint to prove the whole thing. So really, that 600 is -- I mean, you're going to see us do more and more clinical work like that to do a lot of cases, Bob, just to make sure that we have good evidence for our customer base as we go out there to work on. Secondly, when you look at the teen marketplace, palatal expansion, or what we call Phase I, represents about 20% of the marketplace.

    是的。首先,我們做的那 600 個案例——該產品會在 7 月上市。那 600 個其實只是我們從臨床研究的角度所安排的案例,用來驗證整體效果。所以那 600——我的意思是,你會看到我們做越來越多這樣的臨床工作,做很多案例,Bob,只是為了確保當我們對外推廣時,能為客戶群提供充分且良好的證據。其次,當你看青少年市場時,腭擴張(palatal expansion),或我們所稱的第一期(Phase I),約占市場的 20%。

  • Now this is dental expansion. It's not morphology or bone expansion like you have in rapid palatal expansion. So in the past, we've said we've been -- roughly can do 60% to 65% of the cases with Invisalign. What Invisalign First dental expansion does is expand that market served opportunity another 10%, and then we'll follow that with the rapid palatal expander that we're currently going through now, and that will increase it another 10% too so we can cover that whole 20% Phase I part that you have with teens out there.

    這是牙性擴張(dental expansion),不是像快速腭擴張(rapid palatal expansion)那樣的形態或骨性擴張。過去我們說過,使用 Invisalign 大約可以處理 60% 到 65% 的案例。Invisalign First 的牙性擴張所做的是把可服務的市場機會再擴大約 10%,接著我們還會推出目前正在進行中的快速腭擴張器(rapid palatal expander),那也會再增加約 10%,如此我們就能涵蓋青少年市場中那整個 20% 的第一期(Phase I)部分。

  • And that also has a good entrée for us because often it's Phase I, Phase II treatments, where teens or young children, they're at 7 age or 8 age, have the palate expansion play, and then it goes on to dental kind of work from an orthodontics standpoint later on in their teens. And so there's a good transition period for that too. So it's a great product. It's targeting that segment of the marketplace that we haven't had technology at before, and it's specifically an orthodontic product that we've developed here.

    這對我們也有很好的切入點,因為常見的是第一期、第二期治療:青少年或年幼孩童在 7、8 歲時先進行腭擴張,之後在青少年階段再從齒顎矯正的角度進行牙科相關治療。因此中間也有很好的銜接期。這是一個很棒的產品,鎖定的是我們過去沒有技術能涵蓋的市場區隔,而且這是我們在此專門開發的矯正產品。

  • Operator

    Operator

  • Our next question comes from Brandon Couillard of Jefferies.

    我們的下一個問題來自 Jefferies 的 Brandon Couillard。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Joe, to the extent you're comfortable, would love to just hear your view on kind of what the path forward is with respect to SDC, SmileDirect. And then, John, any chance you could share with us the percent of cases that you manufactured for them in the first quarter?

    Joe,在你方便的範圍內,我很想聽聽你對 SmileDirect(SDC)後續發展路徑的看法。然後 John,你是否能分享一下第一季你們為他們製造的案例占比是多少?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • We can't really get into specifics. And obviously, we're going through litigation, and we have to work through litigation. I'd just say we continue to have a good relationship with David and his team, and we just have a disagreement in the sense of obviously the contract that we're in and we're going to work through this from a litigation standpoint. So as that develops, we'll be able to be more clear with you as to what's going on.

    我們無法深入談具體細節。顯然我們正在進行訴訟,也必須透過訴訟程序來處理。我只能說,我們與 David 及其團隊仍維持良好關係,而我們的分歧在於——很明顯——我們所簽訂的合約內容,我們將從訴訟的角度來解決。因此隨著進展,我們會更清楚地向各位說明實際情況。

  • Brandon Couillard - Equity Analyst

    Brandon Couillard - Equity Analyst

  • Fair enough. And then one more, Joe. With respect to the Invisalign store model, would be curious to hear your views on how that's tracking relative to plans. It looks like you pulled forward perhaps by a couple of quarters, the East Coast buildout. What are some of the things you're learning? And what have you learned so far from the initial experience?

    了解。再一個問題,Joe。關於 Invisalign 門市模式,我想聽聽你對其進展相對於計畫的看法。看起來你們可能把東岸的建置提前了幾個季度。你們學到了哪些事情?到目前為止,從最初的經驗中你們有哪些收穫?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Brandon, first of all, we didn't pull those forward. That was in our plan as we had for 2018, and we're just sequentially putting them in. And we've learned -- honestly, these stores, we've learned a lot in a sense in these -- what we learn helps our doctors an awful lot too about how you take a basic consumer and you turn them into a patient. We learned that visualization is really important. The speed of that visualization, I mean, you scan, you can show a patient what their teeth are going to look like with certain kind of treatment options. It gives them a lot of confidence then to go to a doctor and to see a doctor and to complete that treatment piece.

    Brandon,首先,我們並沒有把它提前。那本來就在我們 2018 年的計畫中,我們只是按序逐步設置。我們學到——坦白說——這些門市讓我們學到很多,而我們學到的也能大幅幫助醫師,了解如何把一位一般消費者轉化為病患。我們發現視覺化非常重要,且視覺化的速度也很重要。也就是說,你掃描後就能向病患展示,在某些治療選項下他們的牙齒會變成什麼樣子。這會讓他們更有信心去找醫師、看診,並完成治療的那一段。

  • We've learned a lot about our software, too, in the sense of how it has to respond from a patient standpoint. There's also a lot that we're doing from a marketing standpoint in a sense of turning interest from a consumer over to a store and then back to a doc. In other words, turning consumers into patients also. Through all that, I'll tell you the iTero Scanner again is really critical in being able to do this. It's really the key on the visualization piece. But also our treatment software planning in a sense of making it as realtime as possible so the patients can see how their teeth will move and what their smile will look like, those combinations become really important, not just in the store but as we translate that software to our doctor partners.

    我們也從軟體方面學到很多,尤其是它必須如何從病患角度做出回應。此外,在行銷方面我們也做了很多工作,目的是把消費者的興趣導向門市,然後再導回醫師。換句話說,也是把消費者轉化為病患。透過這一切,我再說一次,iTero 掃描器在能夠做到這些方面非常關鍵。它確實是視覺化環節的核心。但同時,我們的治療規劃軟體也很重要,因為要盡可能做到即時(realtime),讓病患能看到牙齒如何移動、以及笑容會變成什麼樣子。這些組合不僅在門市很重要,當我們把這套軟體轉化給我們的醫師合作夥伴時也同樣重要。

  • Operator

    Operator

  • Our next question comes from John Kreger, William Blair.

    我們的下一個問題來自 William Blair 的 John Kreger。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Joe, can you give us a sense in terms of the feedback that you're hearing from your field sales force on the competitive front? Are you seeing any changes, perhaps in promotional activity or pricing from competitors at least at the low end?

    Joe,你能否就你從前線銷售團隊在競爭面所聽到的回饋,給我們一些概況?你是否看到任何變化,例如競爭對手在促銷活動或定價方面(至少在低端市場)有所調整?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No, we haven't seen any change at all, John. I mean, we -- I mean, the same cast of competitors are still out there that we had before. Obviously, we expect the 3M product at the AAO. We are pretty sure to see one there. We saw the DENTSPLY announcement with the MTM expansion in the 510(k) that they've done. But we haven't seen that translate into any kind of strategy or implementation in the marketplace yet. We [only] expect to see that in the second half.

    沒有,John,我們完全沒有看到任何變化。我的意思是,我們——我的意思是,還是同一批競爭對手,跟以前一樣。顯然,我們預期在 AAO 會看到 3M 的產品。我們相當確定會在那裡看到一款。我們也看到 DENTSPLY 的公告,提到他們在已完成的 510(k) 中擴大了 MTM 的範圍。但我們還沒有看到這些在市場上轉化成任何策略或落地執行。我們[僅]預期在下半年才會看到。

  • Our guess, John, is pretty much what we've been telling you and the rest of the teams over the last couple of years is we expect this to be midrange products, so in the [26 aligner] or less kind of an area. We expect a kind of a slow ramp-up just because of the nature of how you have to scale in this business, take some time in treatment planning and also manufacturing. So I mean, you can see with our kind of bullish forecast for the second half of the year that John just called that we're pretty much -- have this in place in the sense of what we thought we would face, and we haven't really changed that analysis since we put the plan together last year.

    John,我們的猜測基本上跟過去幾年我們一直告訴你以及其他團隊的一樣:我們預期這會是中階產品,也就是在[26 副牙套]或更少的區間。我們預期會是相對緩慢的爬坡,因為在這個產業要擴張規模的特性使然,治療規劃以及製造都需要時間。所以我的意思是,你可以從我們對今年下半年相對偏樂觀的預測(John 剛剛提到的)看出來,我們基本上——已經把這些因素納入考量,符合我們認為會面對的情況;自從去年把計畫訂出來之後,我們並沒有真正改變這個分析。

  • John Charles Kreger - Partner & Healthcare Services Analyst

    John Charles Kreger - Partner & Healthcare Services Analyst

  • Great. And one quick follow-up on the Scanner business. Did you see any kind of stocking by Patterson in the U.S. that might cause sales to slow as we move through this year? Or do you view that as [in-demand] tracking as well as it would appear?

    很好。再追問一個關於掃描器業務的問題。你們是否看到 Patterson 在美國有任何囤貨行為,可能導致我們今年接下來的銷售放緩?還是你認為那也是[按需求]的出貨追蹤,看起來一切正常?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No stocking here, John. In demand. That's a policy we have here.

    John,沒有囤貨。是按需求出貨。這是我們這裡的政策。

  • Operator

    Operator

  • Our next question comes from Erin Wright of Credit Suisse.

    我們的下一個問題來自 Credit Suisse 的 Erin Wright。

  • Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

    Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

  • Can you speak to the more recent financing pilot? I guess, any surprises with that sort of initiative and when that would be a more meaningful contributor to growth?

    你能談談最近的融資試點計畫嗎?我想問的是,這類倡議有沒有任何意外之處?以及它何時會對成長做出更有意義的貢獻?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, the filing -- this is John. For -- Erin, the pilot that we have is -- took place in end of fourth quarter and through the first quarter. We saw great results, and it is going wider across the U.S. starting this quarter, where customers now -- customers and ultimately the patients have a lot more flexibility in terms of how they want to finance and work through the different financing options that they might have.

    是的,這個申請——我是 John。Erin,我們的試點——是在第四季末到第一季期間進行。我們看到非常好的結果,並且從本季開始在全美更廣泛推行,讓客戶——以及最終的病患——在他們想要如何融資、以及如何在可能的不同融資選項之間做選擇方面,有更大的彈性。

  • Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

    Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst

  • Okay. I'll follow up later there. And then on -- can you speak, I guess, on China and the opportunity there, I guess, as well as the competitive landscape, not just maybe from the clear aligner segment but also the broader iTero opportunity with the launch announced today?

    好的。我稍後再追問那部分。然後關於——你能談談中國以及那裡的機會嗎?也包括競爭態勢,不只是透明牙套這個區隔,還有今天宣布推出後更廣泛的 iTero 機會?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I think -- it's back to Joe, Erin. We're excited about that. I mean, our growth to China -- China is our second largest market. Our growth over there has been tremendous. It's hard to believe that right now everything we do in China is basically PVC impressions (sic) [PVS impressions]. So -- and I mentioned in my script about 2% penetration of intraoral scanners in China. So from a competitive standpoint, the market is wide open in a sense, and you could see that from those kind of -- we have to sell. We have to train. There's a lot of things we learned in Japan because of the iTero Scanner being approved in Japan last year in the sense of how you have to ramp up, and a lot of technology and people to bring our customers up to speed, and so all that friction we're anticipating for this year as we ramp up in China. We're putting people in place and training in place to be able to get that done.

    Erin,我想——回到 Joe。對此我們很興奮。我的意思是,我們在中國的成長——中國是我們第二大市場。我們在那邊的成長非常驚人。很難相信的是,目前我們在中國做的幾乎所有事情基本上都是 PVC 印模(原文如此)[PVS 印模]。所以——我在講稿裡也提到,中國口內掃描器的滲透率大約只有 2%。因此從競爭角度來看,市場在某種意義上是完全開放的,你也可以從這些——我們必須去銷售、必須去訓練——看得出來。我們在日本學到很多,因為 iTero 掃描器去年在日本獲准上市,讓我們理解到你必須如何爬坡,以及需要投入大量技術與人力,讓客戶能夠跟上進度;因此我們預期今年在中國推進時也會遇到所有這些摩擦。我們正在配置人員並建立訓練機制,以便完成這件事。

  • Operator

    Operator

  • Our next question comes from Matt O'Brien of Piper Jaffray.

    我們的下一個問題來自 Piper Jaffray 的 Matt O'Brien。

  • Kevin Michael Farshchi - Research Analyst

    Kevin Michael Farshchi - Research Analyst

  • This is Kevin on for Matt today. Wanted to start with the mandibular advancement ramp abroad. Kind of what's most driving that strength? I've heard about it being incredible for the last 2 quarters. And then secondly, with that assuming approval here in the U.S., how fast exactly is the U.S. ramp? Is this something that ortho customers have been asking for, for a long time?

    今天由 Kevin 代替 Matt 提問。我想先從海外下顎前移(mandibular advancement)的爬坡談起。究竟是什麼最主要在驅動那股強勁動能?我聽說過去兩季都非常亮眼。第二,假設在美國這裡獲准上市,美國的爬坡速度到底會有多快?這是矯正客戶長期以來一直在要求的東西嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Kevin, it's Joe. First of all, I'd say from a mass standpoint, the ramp overseas, this is just a product that's unique, right? You obviously addressed mandibular issues, and these are people or teens that are between the ages of 10 and 12 usually [with that] bone development from a jaw standpoint. And there's really nothing in the world to tell you, you have twin block and things like this. This looks like a torture device basically with metal that's used to move kids forward with [also] composites. This -- what this does is move your jaw forward with removable aligners and also straightens your teeth at the same time. So it's a true breakthrough for that end of the market, and I think that's why you see really good pickup.

    Kevin,我是 Joe。首先我會說,從整體量的角度來看,海外的爬坡,這是一個很獨特的產品,對吧?它明顯是針對下顎問題,而這些通常是 10 到 12 歲之間的孩童或青少年,[在那個階段]顎骨的骨骼發育正在進行。世界上其實沒有什麼——你有 twin block 之類的裝置。那看起來基本上像是一種酷刑器具,用金屬把孩子往前推,還會搭配樹脂。這個——它的作用是用可拆式牙套把下顎往前帶,同時也把牙齒排整齊。所以對於市場的那一端來說,這是真正的突破,我想這就是你看到採用度很好的原因。

  • Secondly, is all of these products, as it moves in the United States, I wouldn't model some kind of huge increase in teens because of mandibular advancement in the United States. Because there is always a slow takeup of this because orthodontists want to try it, they want to see success with their patients, they build that kind of credibility with the product line, they continue to move on. So from a North America standpoint, this is more of a 2019 discussion with MAF in the sense of maybe significant kinds of opportunities than I would say in the second half of this year.

    第二,這些產品在美國推進時,我不會把它建模成因為下顎前移而讓美國青少年病例出現某種巨幅增加。因為這類產品的採用一向是緩慢的:矯正醫師想先試用、想看到病患的成功案例,建立對產品線的那種信任與口碑,然後才會持續往前推進。所以從北美的角度來看,與其說是今年下半年,我會說這更像是 2019 年、以 MAF 的角度來討論可能出現較顯著機會的議題。

  • Kevin Michael Farshchi - Research Analyst

    Kevin Michael Farshchi - Research Analyst

  • Okay, Joe, that's really helpful. I just had one follow-up on a previous question. On the competitive front and then additionally with the DTC effort, I was just curious. Are you hearing from your customers specifically becoming increasingly aware of additional offerings in your view? And secondly, are they pushing back a little bit on pricing and looking for better discounts and things like this as a result of the DTC effort increasing and then also kind of layering on new products in the next coming years?

    好的,Joe,這很有幫助。我還有一個針對先前問題的追問。關於競爭面,以及另外關於 DTC(直面消費者)的推動,我想請教:你是否聽到你們的客戶在你看來,正變得越來越意識到更多額外的產品/方案?第二,隨著 DTC 力道增加、以及未來幾年又會推出新產品的情況下,他們是否在定價上更常反彈,並尋求更好的折扣之類?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Kevin, I'd say, look, there's increasing awareness because -- I mean, it's mainly SDC in North America has really extensive advertising, and so it's hard to watch TV and not run into an Invisalign ad or an SDC ad in that sense. But I wouldn't say -- our customers always want lower prices, like almost any other customers in the world, in anything else that you sell. So I wouldn't say that the SDC price range has created more sensitivity with our orthodontic and GP customers out there. I will say that there is a price elasticity curve, and obviously, that kind of lower very, I'd say, minor type of tooth movement kind of things that opens up a new segment of the marketplace that frankly hasn't been serviced in a big way before.

    Kevin,我會說,你看,市場的確有更高的認知度,因為——我的意思是,主要是在北美,SDC 的廣告投放非常密集,所以你很難看電視而不看到 Invisalign 的廣告或 SDC 的廣告。但我不會說——我們的客戶總是想要更低的價格,就像世界上幾乎所有客戶一樣,不管你賣什麼都是如此。所以我不會說 SDC 的價格帶讓我們的矯正醫師與一般牙醫(GP)客戶變得更敏感。我會說確實存在一條價格彈性曲線,而顯然,那種較低價、我會說屬於非常輕微的牙齒移動類型,確實開啟了市場上一個新的區隔,而坦白說,以前並沒有被大規模服務到。

  • And so I think it just makes doctors aware of the more of a segmentation in the market, of not doing a full bite correction but just doing maybe your Social 6 or just correcting a smile that someone is not comfortable with. That's a new segment of the market. It's priced in a different way. And I'd say that's not a pushback on us on price. It's more of a look at how to service those patients and what's the best product to do that with.

    因此我認為這只是讓醫師更意識到市場的分眾:不是做完整的咬合矯正,而是可能只做你的 Social 6,或只是矯正一個讓人不自在的笑容。那是一個新的市場區隔,定價方式也不同。我會說這不是對我們價格的反彈,而是更像在思考要如何服務那些病患,以及用什麼產品來做這件事最合適。

  • Operator

    Operator

  • Our next question comes from Steve Beuchaw of Morgan Stanley.

    我們的下一個問題來自 Morgan Stanley 的 Steve Beuchaw。

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • That's a new one. This GP number in the quarter kind of sticks out in a really good way, really on a tougher comp kind of inflects. Is there something going on in GP in the U.S.? I mean, we don't have -- I go out in the field. What was the magic there?

    這是個新鮮的說法。這一季的 GP 數字在很正面的意義上特別突出,尤其是在較具挑戰的比較基期下還出現向上拐點。美國的 GP 端是不是發生了什麼事?我的意思是,我們沒有——我也會到前線跑。那裡的魔法是什麼?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I don't -- it's not magic, and it's not a surprise, Steve. I'd say, first of all, STO -- I mean, the DSO marketplace has been big for us, right? So you know our work with Heartland, what's going on there and some other dental service organizations, teen, and North America has been very good at executing around those opportunities. Secondly, honestly, the increased advertising that we've been doing, okay, has an overall halo effect with driving patients to GPs asking for Invisalign treatment. And we have noticed that since last year, when we started cranking up advertising. So that is a kind of a residual effect or a second-order effect to help the GPPs.

    我不——這不是魔法,也不令人意外,Steve。我會說,首先,STO——我的意思是,DSO 市場對我們一直很重要,對吧?所以你知道我們與 Heartland 的合作、那邊的進展,以及其他一些牙科服務組織;在青少年與北美市場,我們在把握那些機會方面執行得非常好。第二,老實說,我們加大投放的廣告,好嗎,對整體有一種光環效應,會帶動病患去找一般牙醫(GP)詢問 Invisalign 治療。我們從去年開始加大廣告力道後就注意到這點。所以這是一種殘餘效應或次級效應,有助於推動 GP 端的表現。

  • Thirdly, Steve, is we're doing more and more segmentation on salespeople calling on GPs in a GP kind of a way. In other words, understanding GP workflows, they don't want to be orthodontists, having products like that are more simple for them to use in the sense of utilizing that within the workflow of a normal restorative kind of a dentistry type of workflow. So it's those 3 areas primarily.

    第三點,Steve,是我們正以越來越多的方式,針對拜訪一般牙醫(GP)的業務人員進行更細緻的分眾,並以符合一般牙醫(GP)運作方式的角度來做。換句話說,理解一般牙醫(GP)的工作流程;他們不想成為矯正專科醫師,因此需要像那樣更簡單、能在一般修復牙科(restorative)類型的正常牙科工作流程中使用的產品。所以主要就是這三個面向。

  • Stephen Christopher Beuchaw - Equity Analyst

    Stephen Christopher Beuchaw - Equity Analyst

  • Super helpful. And then you guys, you may have set a new record for press releases in one afternoon. I mean, you introduced a lot of new stuff today, and we could spend a lot of time on any one of them. But I wonder if there's any way to give us a sort of high-level view, Joe, on what you think these products mean for the growth profile of the company over the next 2 years, the sum total of getting iTero into China and getting the GP channel a little bit more automated, getting more cameras on the market. What does this mean for the next 2 or 3 years?

    非常有幫助。然後你們今天下午的新聞稿數量,可能創下新紀錄。我是說,你們今天推出了很多新東西,我們可以在任何一項上花很多時間。但我想知道,Joe,你能否用一個較高層次的角度,跟我們說說你認為這些產品對公司未來兩年的成長輪廓意味著什麼——把 iTero 帶進中國、讓 GP 通路更自動化一些、讓市場上有更多相機。這對未來 2 到 3 年代表什麼?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Steve, first to be completely honest with you, too, we're still learning, right? I mean, as you remember like a year ago, we were -- we wouldn't really be tied down, to tell you, that we sell more iTeros and we sell more aligners. Today, we'll tell you very concretely because we have enough data today that we sell more iTeros, we sell more aligners. We're gaining a lot of confidence in APAC as we continue to grow. Like I mentioned on a previous question is, in Japan, we learned a lot about what iTero can do, as you start to ramp up in a new market like Asia. Now Japan is completely different than China, completely in a sense of how you do business there. But we do -- we know how to go in there, and we can anticipate in a sense of what China will need and the kind of uptake we'll have with those kind of scanners.

    Steve,首先完全坦白跟你說,我們也還在學習,對吧?我的意思是,如你記得大概一年前,我們——我們不太會把自己綁死,跟你說我們賣更多 iTero 就會賣更多隱形矯正器(aligners)。今天我們會非常具體地告訴你,因為我們現在有足夠的數據:我們賣更多 iTero,就會賣更多隱形矯正器。我們在亞太(APAC)持續成長的同時,也建立了很大的信心。就像我在前一個問題提到的,在日本,我們學到很多關於 iTero 能做什麼,當你開始在像亞洲這樣的新市場加速擴張時。現在日本和中國完全不同,尤其在做生意的方式上完全不同。但我們確實——我們知道如何進入那裡,也能在某種程度上預期中國會需要什麼,以及這類掃描器會有怎樣的採用速度。

  • So the iTeros that we just announced, the 2 products in iTero. Remember, this is equipment business. I grew up in equipment business and medical. You know that these are platforms, right? These are new platforms that we're moving forward on to help to extend what we already know in that sense. So like the Flex product allows you to put it into a compatible computer, move it around to different offices. It's what our customers are basically asking for. It's not break -- new breakthrough in scanner technology. It's an extension. You're going to see us continue to do that as we work off a successful platform that allows us not to just go wider from a geographical standpoint like China but to go deeper in the sense of the workflow and what our orthodontists and our GPs really want out there.

    所以我們剛宣布的 iTero,也就是 iTero 的兩項產品。記住,這是設備業務。我是在設備與醫療產業長大的。你知道這些是平台,對吧?這些是我們正在推進的新平台,用來在既有認知的基礎上延伸能力。比如 Flex 產品讓你可以把它接到相容的電腦上,帶著到不同診所移動使用。這基本上就是客戶在要求的。這不是——掃描器技術上的全新突破,而是一種延伸。你會看到我們持續這麼做:在一個成功的平台上繼續開發,讓我們不只是從地理角度往外擴(例如中國),也能在工作流程層面往更深處走,去滿足我們的矯正醫師與一般牙醫(GP)真正想要的東西。

  • Now I would look at -- when you look at Invisalign Teen First, the product we just announced, that's truly a breakthrough. When you think for years, we really couldn't do teeth that weren't completely erupted, that didn't have permanent dentition. Now we threw a lot of technology and understanding over the year we can predict what those eruptions are going to be, and that's what we've programmed into that Teen First product line. That's why it opens another 10% market share for us. But you've been with us long enough, Steve, to understand that the takeup of those things are always cautious, and it takes time, but it does establish that. And when we do the rapid palatal expansion, that will establish another 20% of the marketplace that we haven't had before. So I mean, just look at this as the continual march of Align Technology to broaden overall our opportunities from a depth standpoint of penetrating the marketplace and from a breadth standpoint in moving into new geographies with those technologies, too.

    現在我會這樣看——當你看 Invisalign Teen First,也就是我們剛宣布的產品,那真的是一個突破。你想想,多年來我們其實無法處理那些尚未完全萌出、還沒有恆牙列(permanent dentition)的牙齒。現在我們投入了大量技術與多年累積的理解,能夠預測那些萌出會如何發生,而這就是我們編入 Teen First 產品線的內容。這也是為什麼它能為我們再打開額外 10% 的市場份額。但你跟我們夠久了,Steve,你也知道這類產品的採用一向會比較謹慎,需要時間,但它確實能建立起來。而當我們做快速上顎擴弓(rapid palatal expansion)時,將會再建立我們以前沒有覆蓋到的另外 20% 市場。所以我的意思是,把這看作 Align Technology 持續前進的步伐:從深度來看是加深對市場的滲透、擴大整體機會;從廣度來看則是藉由這些技術進入新的地理市場。

  • Operator

    Operator

  • Our next question comes from Ravi Misra of Berenberg Capital Markets.

    我們下一個問題來自 Berenberg Capital Markets 的 Ravi Misra。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • Couple of questions, one on the store pilot. Just kind of trying to get a sense for what the revenue potential that you see out of that is in the long term. It sounds like you're having us moderate some of our expectations here based on what the contribution could be from SmileDirect itself as you guys work through your negotiations with them. And if you could give us some information on that, that would be great. And then secondly, maybe just a housekeeping question, just on the EPS line, the 5 points of currency. What was the flow-through down to the bottom line on that?

    兩個問題:第一個是關於門市試點(store pilot)。我想大概了解一下,你們長期看到的營收潛力是什麼。聽起來你們希望我們在這裡把一些預期調低,因為你們正在與 SmileDirect 本身進行協商,來釐清它可能帶來的貢獻。如果你能提供一些相關資訊就太好了。第二個可能是個例行問題:關於 EPS 那一行,匯率帶來的 5 個百分點影響,流到最終獲利端的影響是多少?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • John, take that last question.

    John,你來回答最後那個問題。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, on the -- I'll take that first, Ravi, on the EPS. We saw 5 points on revenue. And the way our model works is, usually, we got about 3x the benefit on revenue as it is to profitability.

    好的,關於——我先回答第一個,Ravi,關於 EPS。我們在營收端看到 5 個百分點的影響。而我們的模型運作方式是,通常營收端的好處,對獲利的貢獻大約是 3 倍的槓桿。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Ravi, on the store pilot, we were not going to share any data on the store pilot right now. We call them pilots for a reason because we're learning, and we're growing through that learning. And as this becomes more understandable because we have more data points, we'll be happy to share that with you. As far as the SDC and all, we haven't shared specifically what we expect from quarter-to-quarter. I have never wanted you to really [evaluate] Align stock on SDC, we sell to SDC. [I never wanted] to do that. And so when you say we're kind of moderating your views of volume, I would say we're talking lower 30% for this year. That's not a moderation in the sense of what we think the growth is. We just want you to not try to handicap that with the SDC volume. This is our inherent volume that we're generating in this business.

    Ravi,關於門市試點,我們目前不會分享任何門市試點的數據。我們之所以稱之為試點,是有原因的,因為我們正在學習,並在學習中成長。當這件事變得更可理解、因為我們有更多數據點時,我們很樂意再與你分享。至於 SDC 等等,我們並沒有具體分享我們預期每季會有多少。我從來不希望你真的把 Align 的股票用 SDC 來[評估]——我們是賣給 SDC 的。[我從來不希望]這樣做。所以當你說我們在某種程度上調低你對量的看法,我會說我們談的是今年低 30% 的成長。這不是在調低我們對成長的看法;我們只是希望你不要用 SDC 的量去推算或猜測。這是我們在這個業務中自身所產生的內生成長量。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • Yes, and I think that's pretty clear given your case start [flat] guidance in the low 30s now. So I appreciate that. And then finally just on the reapportionment of the Latin American sales. Can you just talk about whether that's going to -- is that just a reporting issue? Or are you going to be realigning some of the business units internally as well with that?

    是的,而且考量到你們現在在低 30% 的 case start [持平] 指引,我覺得這點很清楚,所以我很感謝。最後一個問題是關於拉丁美洲銷售的重新歸屬(reapportionment)。你能談談這是否只是報表呈現上的問題?還是你們也會在內部重新調整一些事業單位的配置?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • So I mean, that -- what that does, Ravi, is we have a regional strategy here, right? So we have APAC from an Asia standpoint. We have EMEA from Europe. We've always had this North American organization, and it's been kind of -- Latin America was reporting into another part of the organization. And so this just straightens out our organizational intention of having regions in each one of the 3 key areas in. But frankly -- and then we bought up our distributorships in those areas in Latin America and also Brazil, and we're moving forward in those areas. So you saw how many doctors we trained in Brazil alone. These are good opportunities for us and allows us to focus on it in more of a regional sense and be able to transfer best practices within the Americas throughout the organization. So it's just a move that's in line with our regional structure.

    所以我的意思是,Ravi,那樣做的結果是:我們這裡有一個區域策略,對吧?從亞洲角度我們有 APAC;從歐洲角度我們有 EMEA。我們一直都有北美組織,而過去——拉丁美洲是向組織內的另一個部分彙報的。所以這只是把我們的組織意圖理順:在三個關鍵區域各自建立區域架構。但坦白說——另外,我們也在拉丁美洲那些地區以及巴西收購了經銷權(distributorships),並在那些地區持續推進。所以你也看到我們光是在巴西就訓練了多少位醫師。這些對我們是很好的機會,也讓我們能以更區域化的方式聚焦,並能在美洲各地於組織內部移轉最佳實務。所以這只是符合我們區域架構的一項調整。

  • Operator

    Operator

  • Our next question comes from Jon Block of Stifel.

    我們下一個問題來自 Stifel 的 Jon Block。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • So maybe 2. The first one, just on the new I Go sort of iTero offering, is there a price point on that product? I didn't see it in the release. And clearly, you don't seem overly concerned with competition. But with that new I Go iTero offering, I believe it's up to 20 stages. Joe, is that sort of the part of the market that you do view as most susceptible when the competition does come in the next couple of weeks, where they're going to try to crack the code a bit? And then I've got a follow-up.

    那我可能有兩個問題。第一個是關於新的 I Go、算是 iTero 的一種方案:那個產品有定價嗎?我在新聞稿裡沒看到。而且很明顯你們似乎不太擔心競爭。不過就這個新的 I Go iTero 方案來看,我相信它最多到 20 個階段(stages)。Joe,當競爭對手在接下來幾週進來、試著摸索切入點時,你們是否認為這就是市場中最容易受到影響的那一段?然後我還有一個追問。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Jon, you know this well in your analysis, right? If you take 15 up to 26, I mean, that's been kind of a vacancy in the product portfolio for years. And so I Go wasn't derived without an understanding of that, okay? Yes, we do -- I wouldn't call that -- when you do really stand back from this, trying to do a full case with all the complexity that has to do with full cases, if you were a competitor coming in here, it's a very difficult thing to do. You want to kind of gradually learn and ramp up to that. So the logical -- our logical conclusion is, yes, I mean, we'll probably going to see more competition in the below 30 area. The good thing about that, Jon, that's not new to us. We've seen competition from MTM and Angel Align, and you can go down the list of competitors we've seen globally, ClearCorrect or whatever in that specific area.

    Jon,你在分析裡很清楚這點,對吧?如果你看 15 到 26,我的意思是,那一直是產品組合裡多年來的一個空缺。所以 I Go 的推出不是在不了解這點的情況下做出來的,好嗎?是的,我們確實——我不會把那稱為——當你真的退一步看,想要做一個包含所有複雜度的全病例(full case),如果你是要進來的競爭者,這是非常難做的事。你會想要逐步學習、逐步爬坡到那個程度。所以我們的邏輯結論是,是的,我的意思是,我們可能會在 30 以下的區間看到更多競爭。好的一點是,Jon,這對我們不是新鮮事。我們已經看過來自 MTM 和 Angel Align 的競爭,你也可以把我們在全球看到的競爭者一一列出,例如 ClearCorrect 或其他,在那個特定區間都是如此。

  • But when you look at [Maui], when you look at I Go, Maui was the structure we put in place or whatever, it just gives us more flexibility for our customers to be able to offer these products up and down the range than what we've had before. So yes, could we respond better to competition? Yes. Is that an area we think they'll come in? Yes, but we've already seen that, and this is just a continuation of how we've been working with our customers and how we structure our product portfolio.

    但當你看待[Maui]、看待 I Go 時,Maui 是我們所建立的架構或諸如此類的安排,它只是讓我們能為客戶提供比以往更大的彈性,得以在整個產品區間上下提供這些產品。所以,是的,我們能否更好地回應競爭?可以。我們是否認為他們會在這個領域切入?是的,但我們其實已經看到這種情況,而這只是我們一直以來與客戶合作方式以及我們如何建構產品組合的延續。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Okay. Great. I appreciate you read the reports, Joe. I just need others to as well. Just to pivot for a moment. The scanners in driving utilization in the U.S., that's clearly played a big role over the past several years. And we're seeing the scanners playing a bigger role globally, and you mentioned just starting to get into China. When you take a step back, is there any reason why the utilization step-up, which you now seem much more comfortable sort of verifying that that utilization step up would be any different globally, especially someplace like China or Japan versus what we've seen in North America? In other words, when we look out 2 or 3 years from now, could that be sort of the next leg of growth in some of these more emerging markets?

    好的。很好。我很感謝你有讀報告,Joe。我只是也需要其他人同樣去讀。先稍微轉個話題。掃描器在推動美國的使用率方面,過去幾年顯然扮演了很大的角色。而我們也看到掃描器在全球扮演更大的角色,你也提到才剛開始進入中國。退一步來看,有沒有任何理由認為使用率的提升——你現在似乎更有把握去驗證這個使用率提升——在全球會有所不同,特別是在像中國或日本這樣的地方,相較於我們在北美看到的情況?換句話說,當我們展望兩到三年後,這會不會成為這些較新興市場的下一段成長動能?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • To answer that question, just a flat out yes. I mean, I don't think it's going to be any different in China. It hasn't been different in Japan. We saw an uptake with the customers that took the initial iTeros there, Jon, significantly. So we expect China to be the same way, and other countries, too. In Brazil, I think we've been successful with iTero in Brazil also. So yes, that is another component of growth in the company overall. What's great is it's synergistic growth, right? You have equipment growth, but it really leads to the growth of our core product line, which is Invisalign.

    要回答這個問題,直接說就是會。我的意思是,我不認為在中國會有任何不同。在日本也沒有不同。我們看到那些最初在那裡採用 iTero 的客戶,Jon,使用量顯著提升。所以我們預期中國也會是同樣的情況,其他國家也是如此。在巴西,我認為我們在巴西推動 iTero 也很成功。所以是的,這也是公司整體成長的另一個組成部分。很棒的是,這是協同式成長,對吧?你有設備成長,但它確實會帶動我們核心產品線——也就是 Invisalign——的成長。

  • Operator

    Operator

  • Our next question comes from Richard Newitter of Leerink Partners.

    我們下一個問題來自 Leerink Partners 的 Richard Newitter。

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • Just the first one. On the tax rate, so 13% for 2Q, just wondering, what should we be modeling for the full year?

    先問第一個。關於稅率,第二季是 13%,想請問全年我們應該用什麼數字來建模?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • The guidance that we had given for total year was -- earlier on was 18%. So 18% in total would be what you should use, Richard.

    我們先前給出的全年指引是——在更早之前——18%。所以全年合計 18% 會是你應該採用的數字,Richard。

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • Okay. So that's unchanged. And then, Joe, just going back to a question that was asked earlier on competition and how, if at all, it's factored into your outlook. I guess, can you comment on more specifically how you contemplated the impact of any incremental competition on your prior outlook? And I appreciate you've revised your outlook upward, and that's a bullish signal. But compare the current factoring of competition compared to kind of how you thought about it previously, and if could you get as specific as possible. Is it price? Is it maybe just a little less utilization you otherwise would've felt comfortable providing to The Street? Just how are you thinking about that and quantifying it.

    好的。所以這沒有改變。接著,Joe,我再回到先前有人問到的競爭問題,以及你們是否、以及如何把它納入展望。我想問的是,你能否更具體地說明,你們在先前的展望中是如何考量任何新增競爭所帶來的影響?我也理解你們已把展望上修,這是偏多的訊號。但請比較一下目前對競爭的納入方式,與你們先前的思考方式有何不同,並且如果可以的話請盡量具體。是價格嗎?還是可能只是使用率略低於你原本願意對市場提供的水準?你們到底如何思考並量化這件事?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • It hasn't changed for a year, honestly. I mean, you can tell what we initiated during the beginning of the year. We didn't think we'd have any really major competitive plays in that sense. We knew we'd see more competition. But we've basically looked at our business with the momentum of the business and projected that forward, and you're seeing it within our numbers. There's no specificity that I want to share in the sense of what we think and how much in ASP and what areas. Just take a look at our bullish forecast going forward. And as competition becomes more visible to us and more in line, we'll share with you what we're seeing and how we look at the business.

    老實說,一年來都沒有改變。我的意思是,你可以從我們在年初啟動的事情看得出來。我們不認為在那個意義上會出現任何真正重大的競爭動作。我們知道會看到更多競爭。但我們基本上是以業務的動能來看待我們的業務,並把它向前推估,而你也在我們的數字中看到了。就我們的想法、以及我們認為 ASP 會受到多少影響、會在哪些領域等,我不想分享具體細節。你只要看看我們對未來偏多的預測即可。隨著競爭對我們而言變得更清晰、也更成形,我們會與你分享我們看到的情況,以及我們如何看待這門生意。

  • Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

    Richard S. Newitter - MD, Medical Supplies & Devices and Senior Analyst

  • And a similar follow-up to that line of questioning. Anything baked into your outlook specifically for mandibular contributing in the back half? I know you expect approval, but is there anything baked in for actual contribution to revenue? And same on iTero. It feels like that came -- the approval in Japan -- China came a little bit ahead of plan. I thought you had been talking about a second half kind of ramp for that and approval for that. Was that a little earlier than expected?

    沿著這條提問再追問一個類似的問題。你們的展望中是否有特別把下半年 mandibular(下顎前移)納入?我知道你們預期會獲得核准,但是否有把實際對營收的貢獻納入?iTero 也是一樣。感覺日本的核准——以及中國——似乎比計畫稍微提前。我原本以為你們談的是下半年才會逐步拉升並取得核准。這是否比預期更早?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • First of all, in MAF, no, I wouldn't plan on anything from a -- that would be material in MAF, as I mentioned, and the other thing for the -- for North America when we finally get it approved. On China, we were happy to move that through. We've had good work with our Chinese partners over there to move it through. Right now, we're not calling any upside on that. I mean, we're -- as we indicated, we've had good iTero growth. We think that'll continue. As we -- it's not just about how fast you can sell iTero in China. There's a lot of infrastructure work you have to put in place as far as training and putting things in place to be able to sell through China from an infrastructure standpoint. So what's great about that is we can kind of get a quarter up on that. If it would've been the second half of the year, then we wouldn't have as much opportunity to be able to move that product.

    首先,在 MAF 方面,沒有,我不會把任何——如我提到的——在 MAF 會具重大性的東西納入規劃;另外一個是——針對北美——等我們最終取得核准時也是如此。至於中國,我們很高興能把流程推進。我們與當地的中國合作夥伴合作得很好,讓它得以推進。就目前而言,我們沒有把任何上行空間(upside)納入。我是說,我們——如同我們所指出的——iTero 成長良好,我們認為這會持續。因為——這不只是你能多快在中國賣出 iTero 的問題。你必須在培訓等方面建立大量基礎設施,從基礎建設的角度把各項安排到位,才能在中國推進銷售。所以這點很棒,因為我們可以在這方面提前一個季度。如果原本是在下半年,那我們能推動該產品的機會就沒有那麼多。

  • Operator

    Operator

  • Our next question comes from Steven Valiquette of Barclays.

    我們下一個問題來自 Barclays 的 Steven Valiquette。

  • Steven J. James Valiquette - Research Analyst

    Steven J. James Valiquette - Research Analyst

  • I guess for us, just 1 or 2 quick follow-ups here on the addressable market. First, probably an easy one, but just to make sure to clarify here. When we're talking about this 20% of untapped orthodontic case starts you can now treat with Invisalign First, that 20%, that is within the prior industry view of roughly 10 million worldwide annual orthodontic case starts. Is that correct?

    我想就可服務市場(addressable market)再追問 1 到 2 個簡短問題。第一個可能很簡單,但只是想確認釐清一下。當我們談到這個「你們現在可以用 Invisalign First 治療的、尚未被開發的矯正病例起始(case starts)中的 20%」時,這個 20% 是在先前產業對全球每年約 1,000 萬例矯正病例起始的看法之內。這樣理解正確嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Steve, first of all, it's not 20, okay? Invisalign First is about 10% because that's dental expansion, which means you're just really taking the teeth and rounding the arch, right? Rapid palatal expansion moves the bone, moves the palate out. So it's 10% that more of the market would be Invisalign First, another 10% would be for rapid palatal expansion.

    Steve,首先,不是 20%,好嗎?Invisalign First 大約是 10%,因為那是牙弓擴張(dental expansion),也就是你基本上只是把牙齒移動、把牙弓變圓,對吧?快速腭擴張(rapid palatal expansion)是移動骨頭、把上顎腭部向外擴。所以有 10% 的市場會更適用 Invisalign First,另外 10% 會是快速腭擴張。

  • Shirley Stacy - VP of Corporate Communications and Investor Relations

    Shirley Stacy - VP of Corporate Communications and Investor Relations

  • Steve, you're talking 20% of cases are related to Phase I, and that's correct. What Joe is explaining is -- you're talking about TAM, right?

    Steve,你說的是有 20% 的病例與第一期(Phase I)相關,這是正確的。Joe 在解釋的是——你是在談 TAM(總可服務市場),對吧?

  • Steven J. James Valiquette - Research Analyst

    Steven J. James Valiquette - Research Analyst

  • More on the TAM. That's correct. And really, I mean, the more important question I wanted to get to at the end of the day really was that when we think about the 10 million worldwide orthodontic case start TAM, I guess my real more critical question here is once Invisalign First is generally available and also once you do have U.S. approval for mandibular advancement, I'm just curious where we would spend after those events just on the approximate percent of that 10 million worldwide orthodontic case starts do you think you could treat right now overall with the overall Invisalign product portfolio and approval? That's really the more important question I wanted to ask.

    更進一步談 TAM。沒錯。而且其實,我的意思是,我最終真正想問的更重要問題是:當我們思考全球每年 1,000 萬例矯正病例起始的 TAM 時,我更關鍵的問題是,一旦 Invisalign First 全面上市、以及一旦你們在美國取得 mandibular advancement(下顎前移)的核准之後,我很好奇在那些事件之後,就大約比例而言,在這全球每年 1,000 萬例矯正病例起始中,你認為以目前整體 Invisalign 產品組合與核准範圍,總體上現在可以治療多少百分比?這才是我更想問的重要問題。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I think the simple one on that, Steve, is that before Invisalign First, we said 60%. Invisalign First takes us to 70%. Once we get rapid palatal expansion, it takes us to 80%. And that's the 10 million case starts that are out there, though, that's based on 25% adult and 75% being teens. So if you really want to nail that number, you're going to have to take 75% of 10 times 0.8.

    我認為這個問題的簡單回答是,Steve,在 Invisalign First 之前,我們說是 60%。Invisalign First 讓我們到 70%。一旦我們取得快速腭擴張,就會到 80%。而這是針對外面那 1,000 萬例病例起始,不過那是基於 25% 成人、75% 青少年。若你真的要精確算那個數字,你得用 10 的 75% 再乘以 0.8。

  • Operator

    Operator

  • Your final question comes from Jeff Johnson of Robert W. Baird.

    你們最後一個問題來自 Robert W. Baird 的 Jeff Johnson。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Let me go after the competition question, maybe one other way here. I think we're all trying to circle around different things. But you guys are launching obviously a ton of stuff right now with the I Go and the Phase I and iTero expansion, all that stuff. What's your view? In the second half here, you guys expand the market quite a bit, and so competition gets some share, but you guys are expanding market so fast that you can put up that solid -- that very strong second half guidance that seems to be implied there now. Or do you just really think competition doesn't get much traction? Your comps get tougher in that, so it's getting a little messy to try to figure out kind of how much of this is market expansion, how much maybe competition is or isn't having an impact. But just conceptually, how do you think it plays out that way?

    我換個方式來問競爭這個問題,或許再加一個角度。我想我們都在嘗試從不同面向繞回同一件事。但你們現在顯然推出了大量新東西,包括 I Go、Phase I、iTero 擴張等等。你們怎麼看?在下半年,你們把市場擴大了不少,因此競爭對手拿到一些份額,但你們擴張市場的速度非常快,以至於你們仍能給出那個穩健——那個看起來現在所暗示的、非常強勁的下半年指引。還是你們真的認為競爭不會獲得太多動能?你們的比較基期也變得更具挑戰,所以要釐清到底多少來自市場擴張、多少可能是競爭是否造成影響,會有點混亂。但就概念上,你們認為事情會如何發展?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Jeff, I think the best way to look at this is don't look at this as binary, the competition comes in and just takes our share. We actually think the competition to a certain extent will lift share because it'll give more legitimacy to clear aligners. And so possibly, in that lower segment of the marketplace, could we lose some share? Sure. Sure, we could, at the same time, we're expanding on the upper end with our product lines that you just saw with obviously mandibular advancement in teen and I Go in those areas. Jeff, the other side of this, too, is it's -- we've been saying this for a long time, it's hard to do this. I mean, treatment planning facilities; making sure that you can ship aligners and actually ship them in sequence, so first, second, third or really first, second, third aligners; putting a sales team out there that really can really walk through customers and hold their hand in a sense. But it takes time to do this. It's not -- this is not like a patent cliff we've been saying all along, that's something is a biosimilar, and you can put it in your portfolio and sell it the next day. It's not like that. It'll take time to ramp for our competition.

    Jeff,我認為看待這件事最好的方式是,不要把它當成非黑即白:競爭者進來就直接把我們的市占拿走。我們其實認為,競爭在某種程度上會提升市占,因為它會讓透明牙套(clear aligners)更具正當性與可信度。因此,在市場較低端的那一段,我們可能會流失一些市占嗎?當然。當然有可能;但同時,我們也在高端市場擴張,透過你剛看到的產品線——很明顯包括青少年下顎前移(mandibular advancement)以及 I Go 等領域。Jeff,另外一點是——我們講了很久——這件事很難做。我的意思是,治療規劃設施;確保你能出貨牙套,並且能按序出貨,也就是第一副、第二副、第三副,或更確切地說第一、第二、第三副牙套;建立一支銷售團隊,能真正帶著客戶一步步走、某種程度上像是手把手協助。但這需要時間。這不是——我們一直在說——這不是像專利懸崖那樣的情況;那種是生物相似藥,你可以把它放進產品組合,隔天就能賣。這不是那樣。競爭對手要拉升規模需要時間。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Yes. No, that makes sense. And then one last question for me. Just iTero, anything qualitatively you can talk about, maybe scanner sales in the U.S.? And are you seeing any traction outside of Invisalign cases with iTero on any kind of restorative procedures, anything like that? Just kind of trying to get to what is the mindset of the U.S. dentists right now? Are they willing? Are they at the point where they're wanting to use scanners for things, obviously for Invisalign, but for other things as well. Just what's your view there would be helpful.

    是的。不,這樣就說得通。那我最後一個問題:關於 iTero,有沒有任何定性層面的資訊可以談談,例如美國的掃描器銷售?另外,除了 Invisalign 病例之外,你們是否看到 iTero 在任何修復性(restorative)療程上有一些進展或採用度,例如之類的?我只是想了解一下目前美國牙醫的心態是什麼?他們願意嗎?他們是否已經到了想用掃描器來做事情的階段——當然包括 Invisalign,但也包括其他用途。你對此的看法會很有幫助。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. I mean, if you look at the 3Shape and us, right, I mean, 3Shape has a good position with GPs in the sense of restorative workflow and with labs and whatever. They have helped from a GP standpoint to grow the marketplace. We're the same way. We have a good restorative scanner. We have a great scanner from an overall Invisalign standpoint. And both of us kind of raise the awareness and capability out in the marketplace. So honestly, when you look at this thing, Jeff, long term, this is -- you're going to have a scanner. One way or another, your workflow is going to be digital going forward in dentistry. It starts around these kind of application restorative versus aligners and those kind of things. It'll flow through for the rest.

    是的。我的意思是,如果你看 3Shape 和我們,對吧,3Shape 在一般牙醫(GP)的修復性工作流程,以及與牙技所(labs)等方面有不錯的地位。他們從 GP 的角度幫助市場成長。我們也是一樣。我們有一款很好的修復性掃描器;從整體 Invisalign 的角度來看,我們也有一款很棒的掃描器。我們兩方都在市場上提升認知與能力。所以坦白說,Jeff,長期來看,這件事是——你一定會有一台掃描器。不管用什麼方式,未來牙科的工作流程都會走向數位化。它一開始會圍繞這些應用:修復性 vs. 牙套矯正等,然後會延伸到其他所有領域。

  • So I don't know what you're thinking of in the sense of how to model that, Jeff, or what it means. But it just shows you more and more that this isn't just an -- for orthodontists. This is -- we're developing a scanner that's broad across the marketplace too. We want it to function well for a GP in restorative. If you go back to iTero's beginning, right, it was a restorative scanner. When we bought that business, it primarily was in the general dentistry segment. That's what it was developed around. And so I think I reported that we had 2.5 million restorative scans done on iTero. So when our team is out there calling on a GP, we're talking about not just that you can do our aligners with this, we get them confident you can -- this is a great, very accurate restorative scanner that can communicate very well with your dental lab. That's really important in that workflow.

    所以 Jeff,我不確定你在建模時是怎麼想的,或你覺得這代表什麼。但這越來越顯示,這不只是——給矯正專科醫師用的。這是——我們也在開發一款能廣泛覆蓋整個市場的掃描器。我們希望它在 GP 的修復性應用上也能運作得很好。如果你回到 iTero 的起點,對吧,它原本就是一台修復性掃描器。當我們收購那個業務時,它主要是在一般牙科市場區隔。它就是圍繞那個需求開發的。所以我想我曾報告過,我們用 iTero 完成了 250 萬次修復性掃描。因此,當我們的團隊去拜訪 GP 時,我們談的不只是你可以用它做我們的牙套矯正;我們也讓他們有信心——這是一台很棒、非常精準的修復性掃描器,而且能與你的牙技所非常順暢地溝通。這在那個工作流程中非常重要。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Yes. And scanner sales growing in the U.S. still? There's still a good market there for you guys on the scanners side?

    是的。那掃描器在美國的銷售仍在成長嗎?在掃描器這一塊,你們在那裡仍然有不錯的市場嗎?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • No question.

    毫無疑問。

  • Shirley Stacy - VP of Corporate Communications and Investor Relations

    Shirley Stacy - VP of Corporate Communications and Investor Relations

  • You saw the results of the iTero scanner business. You know the vast majority of the business is still in North America.

    你看到了 iTero 掃描器業務的結果。你知道,這項業務的絕大多數仍然在北美。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Yes. Just with the Japan approval and moving Brazil where you did into the Americas, and I just wanted to check on that.

    是的。只是因為日本的核准,以及你們把巴西如同先前所做的那樣納入美洲區,我只是想確認一下這點。

  • Shirley Stacy - VP of Corporate Communications and Investor Relations

    Shirley Stacy - VP of Corporate Communications and Investor Relations

  • Well, thank you, everyone. This concludes our conference call for today. I want to remind everyone that we will be hosting our Investor Day at the Park Central Hotel in New York City on May 23. You can find more information and register directly on our Investor Relations webpage. Hotel rooms under our group block are limited, and the cut off to make your reservation is April 30. We hope to see you all there. If you have any questions, please let us know.

    好的,謝謝各位。今天的電話會議到此結束。我想提醒大家,我們將於 5 月 23 日在紐約市的 Park Central Hotel 舉辦投資人日(Investor Day)。你可以在我們的投資人關係(Investor Relations)網頁上找到更多資訊並直接註冊。我們團體預留房(group block)的房間數量有限,預訂截止日為 4 月 30 日。希望到時能見到各位。如有任何問題,請告訴我們。

  • Operator

    Operator

  • This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.

    今天的會議到此結束。您現在可以掛斷電話線。感謝您的參與。